Media stories about Tabula Rasa Healthcare (NASDAQ:TRHC) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tabula Rasa Healthcare earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.6912505773818 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Tabula Rasa HealthCare Subsidiary CareKinesis Receives Board Certified Geriatric Pharmacist Recognition Across All Clinicians (finance.yahoo.com)
- Tabula Rasa Healthcare Inc. (TRHC) Cut to “Market Perform” at Wells Fargo & Company (americanbankingnews.com)
- BRIEF-Tabula Rasa Healthcare paid $35 mln to Sinfonía Healthcare after merger (reuters.com)
- Tabula Rasa Healthcare (TRHC) Presents At 2017 Wells Fargo Healthcare Conference – Slideshow (seekingalpha.com)
- Tabula Rasa HealthCare (TRHC) Reports Acquisition of SinfoniaRx (streetinsider.com)
A number of research analysts have commented on TRHC shares. UBS AG boosted their price target on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, August 30th. Chardan Capital boosted their price target on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $16.00 price target on shares of Tabula Rasa Healthcare in a research report on Friday, July 14th. Zacks Investment Research raised Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Finally, Wells Fargo & Company cut Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and boosted their price objective for the stock from $17.00 to $21.00 in a research report on Thursday, September 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $19.43.
Tabula Rasa Healthcare (NASDAQ TRHC) traded up 8.08% during midday trading on Wednesday, hitting $23.80. The stock had a trading volume of 150,303 shares. The company’s 50 day moving average is $21.82 and its 200 day moving average is $16.38. The company’s market cap is $411.41 million. Tabula Rasa Healthcare has a 1-year low of $10.39 and a 1-year high of $24.15.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.06. The company had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The firm’s revenue was up 32.6% compared to the same quarter last year. On average, equities analysts anticipate that Tabula Rasa Healthcare will post $0.41 earnings per share for the current fiscal year.
In other Tabula Rasa Healthcare news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $17.21, for a total value of $137,680.00. Following the sale, the chief executive officer now directly owns 918,362 shares in the company, valued at approximately $15,805,010.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 45.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/09/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-tabula-rasa-healthcare-trhc-stock-price.html.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.